EDISON EQUITY RESEARCH - ALEXZA PHARMACEUTICALS
April 09 2015 - 10:01AM
InvestorsHub NewsWire
EDISON EQUITY
RESEARCH: ALEXZA PHARMACEUTICALS
- EXTENDING PIPELINE WITH AZ-007
GW has initiated its first Phase III pivotal study for Epidiolex in
Dravet syndrome, a highly debilitating and treatment refractory
form of childhood epilepsy. This is the first of four planned Phase
III trials with Epidiolex (one more in Dravet, two in
Lennox-Gastaut syndrome), all due to begin in Q215. Epidiolex is a
major valuation driver, so top-line data by end-2015 from the first
Phase III now underway is a significant catalyst. We also look
forward to further physician-led data to be presented at AAN in
mid-April to highlight Epidiolex’s potential across a wide range of
childhood epilepsies.
GW Pharmaceuticals is a UK-based specialty pharma company focused
on cannabinoids. Sativex is marketed in various European countries
for multiple sclerosis spasticity. Lead pipeline candidate is
Epidiolex for refractory childhood epilepsy, now undergoing Phase
III studies.
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports